Stock AnalizTarsus Pharmaceuticals, Inc. TARS
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026
Tarsus Pharmaceuticals, Inc. (TARS) is a healthcare company listed in the US with a market value of about $4.0B. In the twelve months to September 30, 2026 it had revenue of $682M and net income of -$702M, a net margin of -102.9%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 122.0, a 5-year average ROIC of -30%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 66% below the current price.
Score: 1.6 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $682M | $451M | $183M | $17M | $26M | $57M | $0 | — | — |
| Net income | -$702M | -$66M | -$116M | -$136M | -$62M | -$14M | -$27M | -$5M | -$1M |
| Free cash flow | $32M | -$22M | -$85M | -$119M | -$50M | $3M | -$22M | -$4M | — |
| EPS (diluted) | $-15.18 | $-1.59 | $-3.07 | $-4.62 | $-2.52 | $-0.67 | $-4.32 | $-1.98 | — |
| Net margin | -102.9% | -14.7% | -63.2% | -778.9% | -240.5% | -24.2% | — | — | — |
| ROIC | — | -13.2% | -40.6% | -62.6% | -29.4% | -5.7% | -12.8% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $103.44, 29% above the current price; targets range from $88.00 to $116.00; the consensus rating is “Strong buy”; expected EPS is $-15.32 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Tarsus Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 66% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Tarsus Pharmaceuticals pay a dividend?
Not currently.
Is Tarsus Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Tarsus Pharmaceuticals scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.